Given the above inverse correlation of phopho-ERK5 activation and decreased ER-α expression in breast cancer cell lines (Fig. 1B) we set out to determine if MEK5-ERK5 signaling could play a role in the progression to endocrine therapy resistance. The gene discussed is ESR1; the disease is breast carcinoma.